Improved non-invasive blood glucose monitoring device

Information

  • Research Project
  • 6442444
  • ApplicationId
    6442444
  • Core Project Number
    R43DK059690
  • Full Project Number
    1R43DK059690-01A1
  • Serial Number
    59690
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/20/2002 - 22 years ago
  • Project End Date
    9/30/2003 - 21 years ago
  • Program Officer Name
    SWAIN, AMY L
  • Budget Start Date
    9/20/2002 - 22 years ago
  • Budget End Date
    9/30/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    9/16/2002 - 22 years ago
Organizations

Improved non-invasive blood glucose monitoring device

DESCRIPTION (provided by applicant): The accurate measurement of blood glucose concentration is important in the management of diabetes. Current methods of glucose monitoring involve piercing the skin and collecting blood samples for analysis up to four times daily or more. Even the non-invasive Glucowatch tm glucose monitoring system requires twice daily blood collection for calibration. This original, innovative invention will decrease and maintain the electrical resistance of the skin at a constant level. This allows for a controlled, increased passive or electroosmoticatly driven migration of glucose outwardly through the skin into a biosensor for analysis. By creating a constant permeability and avoiding a capacitance effect, we will be able to reproducibly extract and analyze glucose through the skin, minimizing the need for frequent calibration. Our long-term goal is to commercialize an iontophoretic device that will allow for the accurate and reproducible extraction of glucose from the skin or underlying subcutaneous space. Phase I research will study the linearity between glucose extraction and donor solution concentration in vitro and in vivo and demonstrate the advantage of our approach over the Glucowatch tm We will study glucose flux through human epidermis using a variety of protocols to optimize stratum corneum permeation enhancement and minimize intra- and inter-subject variability.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    140992
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:140992\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ACIONT, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    84103
  • Organization District
    UNITED STATES